Therapeutic process of TTR amyloidosis

Advances in biological understanding of the mechanisms involved in transthyretin (TTR) amyloid formation over the last years have led to the development of modern therapeutic strategies aimed at reducing the deposition of ATTR in the myocardium through stabilization of the circulating TTR tetramer or reduction in hepatic synthesis of TTR. This chapter will discuss the most recent evidence on disease-modifying treatments providing a comprehensive update on current clinical indications and novel molecules under investigation.